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Abstract: Full length (1-84) parathyroid hormone (PTH) was introduced in Europe as a 
treatment for postmenopausal osteoporosis in 2006. The efficacy of PTH (1-84) in the prevention 
of vertebral fractures is very high, and is similar to that of teriparatide. Its action in the prevention 
of femoral fractures has yet to be fully demonstrated, but the incidence of such fractures in trials 
was very low, and a decrease in nonvertebral fractures was seen in high-risk patients. The effect 
on bone mineral density (BMD) was clearly demonstrated in the spine and also in the hip. 
The effects on BMD were evident and increased progressively with treatment until 36 months. 
After its discontinuation there was a clear decrease in BMD if no antiresorptive treatment was 
initiated. Increases in bone volumetric density and bone volume in trabecular sites were also 
reported. Moreover, a bone volume increase was detected in cortical sites. Hypercalcemia and 
hypercalciuria are frequent consequences of PTH treatment, but rarely have clinical effects and 
are usually well controlled by reducing calcium and vitamin D supplementation.
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Introduction
The anabolic effect of parathyroid hormone (PTH) in cancellous bone was suspected 
in primary hyperparathyroidism as long as 20 years ago.1–3 Its use as an anabolic agent 
in the treatment of osteoporosis is based on abundant human and animal literature, 
which led to its intermittent low-dose administration.4–8 The exact mechanisms of PTH’s 
double effect (anabolic with intermittent low dose, and catabolic with continuous high 
dose) are still not completely clear, even though it is well understood that PTH acts 
directly through PTHR1 receptors on osteoblasts to stimulate bone formation and 
also indirectly stimulates differentiation and development of osteoclast cells, leading 
to active bone resorption by increasing the receptor activator of nuclear factor-κB 
ligand and its decoy receptor osteoprotegerin (RANKL/OPG) gene expression ratio.9,10 
The anabolic effect is prevalent during intermittent administration, while osteoclast 
activation occurs with continuous exposure (eg, in primary hyperparathyroidism).11–14 
The anabolic action is observed early in the treatment, while the catabolic action 
appears later.15
The use of PTH as an anabolic agent in the treatment of postmenopausal osteoporosis 
is relatively recent and at present only two different forms of PTH are licensed for this 
purpose: PTH (1-84), or full length PTH, and PTH (1-34), or teriparatide. In the US only 
teriparatide is approved for treatment of postmenopausal osteoporosis, while in Europe International Journal of Women’s Health 2009:1 194
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both are available for this use. Teriparatide has also been 
licensed for glucocorticoid-induced and male osteoporosis. 
Other forms of truncated PTH, PTH (1-31), PTH (1-36), and 
PTH (1-38), have been studied as treatments for osteoporosis, 
but no phase III trials have been completed.16
The commercially available PTH (1-84) (Preotact®; 
Nycomed, Denmark) is manufactured using a strain of 
Escherichia coli modified by recombinant DNA technology. 
The medicinal product is supplied in a dual-chamber 
cartridge: one chamber contains the PTH in powder, the 
other a sterile solvent for reconstitution. The cartridge is 
inserted into an injection pen, which injects subcutaneously 
a dose of 71.4 µL containing 100 µg PTH. Each cartridge 
contains 14 doses and, after reconstitution, has to be stored 
in a refrigerator (2 to 8 °C).17
This review analyses the most recent literature on the 
clinical use of PTH (1-84), focusing on data on efficacy, 
safety, and adherence to treatment.
Clinical trials involving PTH (1-84)
Two large clinical studies – the Treatment of Osteoporosis 
with PTH (TOP) study,18 with its Open Label Extension 
Study (OLES),19 and the PTH and alendronate for osteo-
porosis (PaTH) clinical trial20,21 – laid the foundations for 
the use of PTH (1-84) in the treatment of postmenopausal 
osteoporosis and provided most of the data on its efficacy 
and safety. A number of other studies, some still only at a 
preliminary stage, offer useful information on the clinical 
use of PTH (1-84). These include the phase II safety and 
efficacy trial,4 the Prevention of Osteoporosis in Women 
on Estrogen Replacement (POWER) study,22 the Treatment 
Extension Study (TRES),23 and the Preotact® after a break 
(PEAK) study.24 Other data are taken from abstracts presented 
at recent international osteoporosis meetings. The features of 
the most important studies will be outlined below.
Phase II safety and efficacy trial4
This is a 12-month, double-blind, placebo-controlled, dose-
finding study, which investigated the efficacy and safety of 
human PTH (1-84) in the treatment of postmenopausal osteo-
porosis. It enrolled 217 50- to 75-year-old North American 
postmenopausal women with a lumbar spine bone mineral 
density (BMD), measured by double X-ray absorptiometry 
(DXA), –2.5 standard deviations below the mean peak bone 
mass in young women (T-score ). They had no significant 
medical problems that might affect skeletal homeostasis 
or vertebral abnormalities, and had not received treatment 
for osteoporosis recently. The patients were randomized to 
receive PTH (1-84) at different dosage (50, 75, and 100 µg) 
and placebo, and all patients received daily supplementa-
tion of calcium carbonate (500 to 1000 mg) and vitamin D 
(400 IU). The primary endpoint was to assess the percentage 
change in vertebral BMD from baseline. BMD and bone 
mineral content (BMC) at the femoral site, as well as bone 
marker values were also measured, adverse events collected, 
and compliance assessed.
The TOP study with OLeS and TreS 
extensions
The TOP18 is an 18-month, randomized, double-blind, 
placebo-controlled, parallel-group study performed in 
168 centers in 9 countries, enrolling 2532 postmenopausal 
women with low BMD at the lumbar spine. Women 45 to 
54 years of age (8.1%) were included if BMD was -3.0 
at the lumbar spine, femoral neck or total hip, or if BMD 
was -2.5 and they had 1 to 4 prevalent vertebral fractures. 
Women 55 years of age or older (11.4% 75 years) were 
included if BMD was -2.5, or if BMD was -2.0 and 
they had 1 to 4 fractures. Women were also enrolled even 
if mild hypercalcemia or hypercalciuria (ie, serum calcium 
2.55 to 2.66 mmol/L [10.2 to 10.7 mg/dL] and 24-hour urine 
calcium 7.6 mmol [302 mg]) were present. History of 
metabolic bone disease, significant renal or hepatic disorders 
and recent osteoporosis treatment were exclusion criteria. Of 
the enrolled women 1286 received 100 µg PTH (1-84) and 
1246 placebo, and all received calcium citrate (700 mg/day) 
and vitamin D (400 U/day). The primary endpoint was the 
occurrence of new or worsened vertebral fractures identified 
by radiography. Secondary end outcomes included changes in 
BMD (at the spine, hip, distal radius, and total body), in bone 
turnover markers, and in quantitative computed tomography 
(QCT) for 122 women only. Nonvertebral clinical fractures 
and bone loss were reported as adverse events. The study was 
completed by 1701 women -877 (70%) in the placebo group 
and 824 (64%) in the PTH group. The drop-out rate was high 
in both groups (30% and 26% in the PTH and placebo group 
respectively) but a specific cause has not been identified. 
Even if more patients in the PTH group withdrew consent 
because of adverse events (16%), only a small proportion 
of patients who experienced adverse events discontinued 
participation.
From the TOP study, 1681 patients continued into OLES to 
assess the safety and efficacy of prolonged use of PTH. From 
the PTH group, 781 patients continued the same treatment 
for a further 6 months (a total of 24 months) and were moni-
tored for 12 months after discontinuation; from the placebo International Journal of Women’s Health 2009:1 195
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group 900 patients received the same treatment as the TOP 
PTH group for a further 18 months. Changes in BMD, bone 
turnover markers, and adverse events were monitored.19
One hundred three women, who had been treated for 
18 months in OLES, were screened and 91 included in the 
intention to treat (ITT) group in TRES, after an approximate 
2-month break in PTH treatment between OLES and TRES. 
These patients were treated with PTH (as in the TOP study) 
for a total of 36 months. Changes in BMD and bone turnover 
markers and adverse events were monitored.23
Figure 1 shows the flow chart of all three studies.
The PaTH study20,21
The PaTH study is a randomized, double-blind clinical 
1 + 1 year trial to evaluate whether the concurrent admin-
istration of PTH (1-84) and alendronate would increase 
bone density more than the use of either one alone, in the 
first year, and whether antiresorptive therapy is required to 
maintain BMD increase after 1 year of PTH (1-84) treatment 
(100 µg/day). A total of 238 postmenopausal women (not 
using bisphosphonates) with low BMD at the hip or spine 
(T score  -2.5, or a T score  -2.0 with an additional 
risk factor for osteoporosis) were randomly assigned to 
one of four different regimens – daily treatment with PTH 
in the first and placebo in the second year, PTH in the first 
and alendronate in the second year, PTH + alendronate in 
the first, or alendronate for two years. All patients received 
a supplementation with calcium carbonate (500 mg) and 
vitamin D (400 IU) (Figure 2).
BMD changes at the lumbar spine, hip, and distal radius 
were primary endpoints, assessed by DXA. In a subset of 
204 patients, QCT was also performed at the spine and the 
hip. Markers of bone turnover were measured, adherence and 
adverse events were assessed.
The POWer study22
The POWER study is a randomized, double-blind, 
placebo-controlled, parallel-group study conducted at 
25 clinical centers, designed to evaluate the effects of 
adding PTH (1-84) treatment to women receiving stable 
hormone replacement therapy (HT). Initially planned 
for 24 months, it was modified, following European 
Medicines Agency recommendations on estrogens in 
osteoporosis, and the treatment stopped at 18 months. 
Consequently, ‘18-month’ data represent evaluations 
conducted between 12 and 18 months and ‘24-month’ data 
represent measurements between 18 and 24 months.
The study recruited a total of 187 women, 45 years old 
or more, a minimum of 1 year after menopause, on stable 
HT, and with a BMD T-score  -2.0. Only 124 completed 
the 18 months of treatment, 69 on HT (HT group) and 55 on 
HT and PTH (HT + PTH group), all with calcium (700 mg/day, 
the salt is not specified) and vitamin D (400 U/day) supple-
mentation. The primary efficacy endpoint was change in 
lumbar spine BMD; secondary endpoints were change in 
hip and distal radius BMD, bone turnover markers, height, 
and incidence of vertebral and clinical fractures.
The PeAK study24
The ongoing PEAK study is a 3-year, randomized, multi-
center, open-label, phase IIIb trial investigating lumbar 
spine BMD changes in postmenopausal women with pri-
mary osteoporosis. In the first year of the trial all patients 
were treated with PTH (1-84), and in the second year 
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all patients are being treated with risedronate. In the 
third trial year patients will be randomized and divided 
equally to either continue risedronate treatment or receive 
PTH (1-84). Details on calcium and vitamin D supplementa-
tion are not given. The primary endpoint is to verify increase 
in lumbar spine BMD, but the effect of PTH on calcium 
homeostasis is also being investigated. Postmenopausal 
women (408) aged 50 years with primary osteoporosis 
(lumbar spine T-score  -3.0 SD) were enrolled even if 
pre-treated with bisphosphonates. Women with a serum 
calcium 2.55 mmol/L at baseline and/or calcium metabo-
lism abnormalities were excluded.
Only interim analyses are available – one assessing 
calcium values during the first year of PTH, another evaluat-
ing BMD changes in subjects (27) treated with risedronate or 
alendronate for more than 6 months in the previous year.
Efficacy
The efficacy of PTH (1-84) in the treatment of osteoporosis 
has been evaluated with various endpoints, of which the 
most important is the incidence of new fractures, followed 
by increases in densitometric measurements (using DXA 
(Figure 3) and QCT scans) and variations in bone turnover 
parameters.
Prevention of fractures
The efficacy of PTH (1-84) in the prevention of new vertebral 
fractures in women with or without a prevalent fracture at 
baseline was demonstrated in the TOP study. In this trial the 
incidence of new or worsened vertebral fractures was sig-
nificantly (P = 0.001) lower in treated patients (1.4%) than 
in the placebo group (3.4%), with a 58% (95% confidence 
interval [CI] 0.24 to 0.72) reduction in relative risk (RR). 
The RR reduction for a first vertebral fracture was 68% (95% 
CI 0.14 to 0.75) (P = 0.006) in patients without a prevalent 
fracture at baseline. The number of patients that needed to be 
treated (NNT) for a median of 18 months to prevent a new 
or worsened vertebral fracture was 51 (32 to 129). The NNT 
was 71 (42 to 422) in patients without a baseline fracture, and 
22 (11 to 422) in those with a baseline fracture.18 Recently, in 
a reanalysis of the TOP trial data, the efficacy of PTH in the 
prevention of a new fracture was demonstrated to be greater 
in patients with a low lumbar BMD (T-score  -3.0) at base-
line, with a 74% RR reduction (1.3% vs 5.1%; P  0.001), 
or in patients older than 60 years, with a 64% RR reduction 
(1.5% vs 4.2%; P  0.001).25
During the OLES few new vertebral fractures were 
seen -1 (1.7%) in the group treated with PTH (1-84) for a 
further 6 months, 2 (1.9%) in the 12-month placebo-treatment 
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group, and 4 worsened vertebral fractures in the former 
PTH (1-84)-treated group. The authors suggest that the low 
number of new fractures, during extended PTH treatment 
and after its cessation, confirms the effect of PTH in the 
prevention of osteoporotic fractures.19
In the TOP study there was no detectable effect of PTH 
on nonvertebral fractures (5.8% and 5.6% in the placebo and 
PTH groups, respectively). This may be because the popula-
tion enrolled was younger and with less severe disease than 
in the studies that showed reduced nonvertebral fractures 
in patients treated with teriparatide.26 However, a post-hoc 
analysis of a high-risk subgroup of 231 patients with lumbar 
spine BMD T-scores  -3 showed a 42.8% statistically non-
significant reduction in nonvertebral fractures.27
There were insufficient numbers of vertebral and clinical 
fractures to permit statistical analysis in the POWER trial. 
Three subjects in each treatment group experienced a clinical 
fracture during the study, only one of these in the spine in 
the HT-alone group.22
In the PaTH study, after 2 years, 21 women (8.8%) had 1 
or more clinical fractures, but no differences among groups 
were detected.21
Areal densitometry
The efficacy of PTH has been documented through changes 
in BMD at various sites in many studies. In the TOP trial, 
at month 18 PTH treatment increased lumbar spine BMD 
by 6.5%, compared with a 0.3% decrease in the placebo 
group (P = 0.001).18 There were also significantly greater 
increases in the PTH group in total hip (2.1%), femoral 
neck (2.5%), and trochanter BMD (1.6%).28 At the distal 
radius BMD decreased in the PTH group by a mean of 3.4% 
(P = 0.001).18
Treatment extension for up to 24 months in OLES resulted 
in a continued increase in BMD from baseline, 6.8% in lum-
bar spine and 2.2% in femoral neck.17
The patients treated in OLES and TRES for 36 months 
showed a progressive increase in lumbar spine and total hip 
BMD for the first 18 months (8.0% and 2.1% respectively). 
There was a small decrease (to 7.0% and 1.7%) during the 
approximate 2-month break without treatment. Lumbar 
spine BMD further increased until month 24 of PTH treat-
ment (8.5%) remaining stable for the final 12 months. Total 
hip BMD increased progressively above OLES baseline by 
3.4% at month 36.23
The 24-month data from the TOP and OLES studies was 
analyzed recently by dividing the population into subjects 
with high adherence (80%) and low adherence (80%) 
to the therapy. It was found that the BMD increased by 
8.38% and 4.46% in lumbar spine, and by 2.58% and 1.53% 
in femoral neck, in the high- and low-adherence groups 
respectively.29
Also in the PaTH study, after 1 year of treatment with 
PTH (1-84), the increase in BMD was substantial in lumbar 
spine (6.3%), and very small in total hip (0.3%). A reduction 
(-3.4%) in BMD was seen at the distal radius. In the PTH + 
alendronate and alendronate-alone groups there were lesser 
increases in lumbar spine BMD (4.6 and 6.1%, respectively), 
but greater increases at the total hip and lesser decreases at the 
distal radius (-1.1% in the combination therapy group).20
After the second year of PaTH the BMD increased in 
all four groups at the lumbar spine. The maximum increase 
at the lumbar spine, total hip, and femoral neck (12%, 4%, 
and 4%, respectively) was in the group treated with PTH in 
year one and with alendronate in year two. The minimum 
increase was in the group treated the first year with PTH 
and the second with placebo (4%, 0%, and 1%). The same 
intermediate increase (8%, 3%, and 3%) was also seen in 
the other two groups.21
In the POWER study increases in spine and femoral BMD 
were detected in both groups, with a significantly greater 
increase in the HT + PTH group at the lumbar spine at month 
24 (difference 6.5%, P = 0.001) and at the femoral neck at 
month 18 (difference 1.8%, P = 0.024). A decrease in BMD 
in PTH-treated women was detected at the distal radius, but 
the difference was not significant for the HT-alone group.22
The interim analysis of the PEAK trial showed a median 
increase in lumbar spine BMD of 4.3% in 27 patients 
pre-treated with a bisphosphonate. The upper confidence 
limit was higher than 3%, and therefore pre-treatment with 
a bisphosphonate does not seem to reduce the likelihood of 
a gain in BMD with PTH (1-84) therapy.24
volumetric densitometry
In the TOP trial increases were detected at month 18 in 
trabecular BMD at the spine (37.6%, P = 0.001), total hip 
(4.7%, P = 0.001), femoral neck (4.5%, P = 0.001), and 
trochanter (4.3%, P = 0.001), but there were also increases 
in total hip cortical volume (9.0%, P = 0.003) and total 
hip cortical volumetric bone content (4.8%, P = 0.040). 
A decrease was seen in the total hip cortical volumetric 
BMD (-4.7%, P = 0.001).18
In the PaTH study the volumetric BMD of trabecular 
bone increased at both the spine and the hip in all four 
groups during the two years. After the first year the increase 
in volumetric density of trabecular bone at the spine was International Journal of Women’s Health 2009:1 198
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25.5% in the PTH group, 12.9% in the PTH + alendronate 
group, and 10.5% in the alendronate group. At month 24 
in the PTH + alendronate group the increase was higher 
compared with other treatment regimens, 31% at the spine 
(P = 0.001 vs baseline and other groups) and 13% at the hip 
(P = 0.001 vs baseline). Also the patients treated with combi-
nation therapy and alendronate showed a significant increase 
(11%, P = 0.001 vs baseline) in hip trabecular BMD.21 The 
volumetric BMD in cortical bone at the hip decreased in all 
groups (from -1% to -3%) – the changes were significant 
except in the combination therapy and alendronate group. 
Significant cortical hip volume increases were detected in 
all groups, 1% in PTH/placebo, 6% in PTH + alendronate 
and continued alendronate, and 7% in combination therapy/
alendronate groups.21
An interesting analysis of the data from the PaTH study 
was conducted to correlate structural indices assessed by 
hip structural analysis (HSA)30 and volumetric QCT.44 
The DXA-derived HSA and QCT-derived indices of structural 
geometry in postmenopausal women who received 1 year of 
PTH followed by 1 year of alendronate were significantly 
associated with each other at baseline and showed similar 
improvements at 24 months.31 A finite element analysis with 
simulation for a sideways fall was performed on the hip QCT 
scans of 162 of these subjects. The changes in strength from 
baseline were statistically significant for all four groups at 
year one, but only for three groups at year two – the change 
seen in the PTH-placebo group was, in fact, only 1.17% from 
baseline. Changes in the trabecular density were the major 
cause of strength increases, regardless of treatment group, 
but changes also in cortical density and mass played a role, 
the degree of which depended on treatment.32
Bone turnover
The use of bone turnover markers as indices of efficacy is 
based upon the concept of the ‘anabolic window’, ie, the acti-
vation latency between formation and resorption markers.33
Bone formation markers rapidly increased from baseline 
in PTH-treated patients in all studies. Bone alkaline phos-
phatase (bALP) increased in the TOP study, approximately 
30% at month 1, 100% at months 6 and 12, and 80% at 
month 18 in the PTH group,18 and in the POWER study, 
98% at month 12 and 115% at month 24 in the PTH + HT 
group.22 The elevation of bALP decreased slightly in the 
OLES extension of the TOP study, remaining 27% above 
the TOP baseline.29
Osteocalcin significantly increased dose-dependently in 
the PTH treated group in the phase II study – approximate 
percentage changes are derived from a graph and they range 
from 20% with 50 µg to 45% with 100 µg at month 1, from 
60% to 120% at month 6, and from 75% to 150% at month 
12.4 N-propeptide of type 1 collagen (P1NP) increased 
after 1, 3, and 12 months of PTH therapy (changes derived 
from a graph were approximately 90%, 140%, and 150% 
respectively) in the PaTH study, and rapidly decreased after 
treatment suspension.21
Bone resorption markers also increased in all studies, 
but this increase was somewhat delayed in comparison with 
the change in bone formation markers in the TOP and PaTH 
studies. In the TOP study, a significant increase in urinary 
N-telopeptides of type 1 collagen (NTx) was detectable only 
from month 6 (approximately 150%) to month 18 (85%).4 
Women in the PTH-alone group in the PaTH study showed 
an increase in serum C-terminal telopeptide of type I collagen 
(CTx) from month 3 to month 12 (changes derived from a 
graph were approximately 70% and 105% respectively), and 
an early and persistent decrease in the alendronate group 
(58% at month 1, approximately 70% at month 12) and in 
the PTH + alendronate group (approximately 50% throughout 
the trial).20 At the end of the second year of the PaTH study, 
all the groups showed similar values below baseline, except 
the PTH/placebo group, which returned to baseline values, 
and these were significantly higher than the other groups.21 
Urinary NTx significantly increased also in PTH-treated 
patients in the POWER study (65% at month 12 and 69% 
at month 24).22
Safety
When a new pharmacological therapy is administered to large 
populations of patients it is mandatory to assess the safety 
of the treatment. For PTH (1-84) the principal concerns are 
with hypercalcemia and hypercalciuria, but also osteogenic 
sarcoma and hyperuricemia.34
The overall tolerability of PTH (1-84) in the trials was 
good. A similar number of patients experienced adverse 
events in the TOP study in the PTH and placebo groups 
(94.0% vs 92.9%),18 in the PaTH study in all treatment groups 
(percentage not indicated),21 and in the POWER study in both 
treatment groups (96% PTH + HT vs 93% HT all events, 
26.7% vs 17.8% serious adverse events).22
The patients who discontinued the treatment in the TOP 
study because of adverse events comprised approximately 
16% of the PTH group (nausea 4.4%, headache 1.4%, 
vomiting 1.1%, dizziness 0.8%, and elevated serum calcium 
2.4% or urine calcium levels 0.5%) and 12% of the placebo 
group (only 2% for these combined events).18International Journal of Women’s Health 2009:1 199
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Osteogenic sarcoma
The pivotal registration trial for teriparatide was stopped due 
to the appearance of osteogenic sarcoma in all the Fischer 
strain of rats receiving lifelong high-dose teriparatide.35–37 
Osteogenic sarcoma was also seen in the PTH 1-84 preclinical 
animal data in the rat, with a dose-responsive increased 
incidence (50 to 100 µg/day). A noncarcinogenic dose of 
PTH (1-84) 10 µg/day was identified.38
In humans only one case of osteogenic sarcoma has been 
reported in patients treated with teriparatide. The diagnosis 
was made in the biopsy of a lung lesion in a female smoker, 
but the bone source was not confirmed.39 Since there are 
about 800,000 patients worldwide on teriparatide, and the 
incidence of osteogenic sarcoma in the adult population 
is 1/250,000/year,40 there is no evidence that this case was 
related to teriparatide.34
Furthermore, no abnormal histopathologic findings were 
reported in iliac crest biopsies after 12 and 18 months of PTH 
therapy in a subset of 40 women in the TOP trial18 and after 
36 months in 14 patients in the TRES study.41
In 2008 a Finnish group reported a case of a malignant 
myeloma in a patient after treatment for osteoporosis with 
teriparatide. They were unable to demonstrate any direct 
association, though they found it intriguing that similar 
mechanisms (RANKL/RANK/OPG system) are involved 
in the development of myeloma and during teriparatide 
treatment.42
It seems that there is no real concern about PTH 
having a carcinogenic action in the dose and treatment 
duration approved in humans, but continued monitoring is 
advisable.
Hypercalcemia
The principal physiological role of PTH is to raise calce-
mia during fasting periods, so transitory hypercalcemia is 
expected to occur 4 to 6 hours after PTH injection.34 However, 
an unexpected persistent hypercalcemia was reported in a 
percentage of patients in all trials in which PTH was used to 
treat osteoporosis.34,43 In the TOP trial the number of patients 
with elevated serum calcium concentration (2.66 mmol/L 
or 10.7 mg/dL) in the PTH (1-84) treated group was 27.8% 
compared with 4.5% in the placebo group.18 This incidence is 
greater than that reported in teriparatide trials and in the PaTH 
study (12%),20 and it has been attributed to different levels 
of calcemia at baseline. In the TOP study baseline calcemia 
was greater than 2.55 to 2.66 mmol/L in 8% of women, while 
12% had hypercalciuria.16,44 The incidence of hypercalcemia 
in the PTH (1-84) trials is shown in Table 1.
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An analysis of the data from the PaTH trial focusing 
on hypercalcemia45 suggests that hypercalcemia is more 
frequent in women with higher baseline serum calcium 
or 1,25(OH)2D levels. The risk of hypercalcemia doubled 
with each 0.13 mmol/L (or 0.5 mg/dL) increase in baseline 
serum calcium and with each increase in baseline serum 
1,25(OH)2D concentration of 10 pg/mL. The frequency 
of clinically relevant hypercalcemia, ie, 11.2 mg/dL, 
was similar in the PTH-alone and in the alendronate and 
PTH groups (4% and 3.4% respectively). This study also 
confirmed that changes in calcium levels follow a time 
pattern, rising at the first month, reaching a maximum at 
the third month, and decreasing to baseline values after 
12 months.45 Serum calcium level was found to be normal 
at a second measurement, without any intervention, in 
58% of the previously hypercalcemic women and, after 
discontinuation of calcium and vitamin D supplementa-
tion, in 38%. In 1 patient it was necessary to decrease the 
PTH injection frequency to every other day. Hypercalcemia 
recurred in 4 patients and only in 1 was it necessary to 
suspend calcium supplementation.45 In the PaTH study the 
protocol included a specific algorithm in case of elevated 
levels of serum and urinary calcium – the first step is to 
repeat the serum calcium measurement, and if hypercal-
cemia persists, the second step is to discontinue calcium 
and vitamin D, then to reduce PTH to every other day, and, 
finally, to discontinue PTH.20,45
A 12-month, open label, head-to-head study, comparing 
the effect of PTH (1-84) and teriparatide in 70 women with 
severe osteoporotic vertebral fractures, recently reported a 
similar incidence (31% and 29%, respectively) of patients 
with hypercalcemia (ionized calcium 1.3 mmol/L). 
In the PTH (1-84)-treated group the mean concentration 
of ionized calcium was significantly higher throughout 
the study.46
Summarizing, hypercalcemia is frequently reported in 
PTH (1-84)-treated patients, but usually has no clinical con-
sequences. The frequency of hypercalcemia is clearly related 
to the baseline level of serum calcium, so it is important to 
evaluate serum calcium before starting PTH (1-84) therapy. 
In the presence of high level of serum calcium (1.3 to 
10.5 mg/dL) the risk of hypercalcemia during treatment is 
real and, without other equally valid therapeutic options, 
repeated measurements of serum calcium level are manda-
tory. In any case, all treated patients should have their serum 
calcium measured in the first month and, on the basis of the 
result further measurements should be planned. The blood for 
serum calcium should be drawn at least 16 hours after PTH 
injection.34 If hypercalcemia develops, the PaTH algorithm18 
or the one proposed by Miller34 may be applied.
Hypercalciuria
In the TOP study hypercalciuria occurred in 46% and 23% 
of women receiving PTH and placebo, respectively.18 In 
the POWER trial hypercalciuria was detected in 43.3% of 
the HT + PTH group and in 16.7% of the HT group. In the 
PaTH study, after year one, 9% of enrolled women devel-
oped hypercalciuria, 8% in the PTH-alone group, 11% in 
the combined therapy group, and none in the alendronate 
group.20,45 Hypercalciuria resolved after discontinuing 
calcium and vitamin D in 12 patients (80%), after decreas-
ing PTH injection frequency in 2 patients, and did not recur 
when daily frequency was resumed, and without intervention 
in the remainder. Only 2 patients in the PTH-alone group 
had concurrent hypercalcemia and hypercalciuria. Mean 
urine calcium concentration significantly increased in both 
the PTH-alone and the PTH and alendronate groups, but there 
was no significant difference between the two groups. The 
risk of hypercalciuria increased by 50% with each 50 mg/day 
increase in baseline urinary calcium (relative risk 1.5; 95% 
CI 1.1 to 2.0).45
Data on hypercalciuria in the trials with PTH (1-84) are 
shown in Table 1.
Hyperuricemia
An increase in serum uric acid above the normal range 
was seen in the PTH group in the TOP study by month 18, 
approximately 20% compared to 4.5% with placebo.18 In the 
PaTH study, too, a similarly (61 mmol/L) significant increase 
in the mean serum uric acid concentration was seen in both 
the PTH + alendronate and the PTH-alone groups, and there 
were 2 patients with gout in the combination therapy group 
and 1 in the PTH group.20
Other adverse events
Other common adverse events in PTH (1-84) treated patients 
are nausea, headache, dizziness, back or limb pain, injection 
site complications, and fatigue.
In the phase II trial a non dose-related injection site reac-
tion was the most common complaint in 134 of 217 women, 
but this event is not so widely reported in other studies.4
In the TOP study, PTH (1-84)-treated patients complained 
more frequently of nausea and vomiting than the placebo 
group patients (22.6% vs 9.2%; P  0.001 and 8.0% vs 
4.4%, respectively).18 In the POWER study, nausea was 
more frequent in the HT + PTH group than in the HT-alone International Journal of Women’s Health 2009:1 201
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group (25.6% vs 3.3%).22 Headache frequency was higher 
in PTH-treated patients in the TOP study, 28.5% vs 23% in 
the placebo group (P = 0.001).18 No differences in headache 
frequency between various groups were reported in the PaTH 
study.20,21
In the TOP study PTH induced a slight reduction in hema-
tocrit, hemoglobin, and erythrocyte count at all time points. 
No serious alterations in cardiac rhythm, repolarization, or 
intraventricular conduction were reported.18
Adherence to treatment
Adherence to treatment and compliance in the patients 
treated with PTH (1-84) in the clinical trials is high, when 
reported.
In the phase II trial compliance was very high, at 94.8% 
to 97.6% in all PTH groups, 14% of the patients discontinued 
the treatment, only 38% of these due to an adverse reaction 
and 48% due to study noncompliance.4
In the TOP study, 824 women out of 1286 (64%) in 
the PTH-treated group completed the trial; 186 (14.5%) 
discontinued drug therapy within 3 months. At the time of 
discontinuation the rate of patients treated with refracted 
dose regimens, adopted after adverse events, was higher in 
PTH groups - 21% and 5% of patients took injections every 
other day in the PTH and placebo group, respectively, and 
13% and 4% when the injection was less frequent. Compar-
ing the causes of discontinuation with the placebo group 
the number of drop-outs due to adverse events doubled, but 
serious adverse events, fractures, and confirmed bone loss 
were more frequent in the placebo group.18
In the POWER study the women who completed the 
study amounted to 62% in the PTH + HT group and 93% in 
the HT group, and overall compliance was high (96% and 
97% respectively).22
In the PaTH study 95% of patients completed the first year 
visit, and 75% fully adhered to treatment by injection.20
An improvement in patient compliance and therapy costs 
could be achieved by a refraction of injection frequency. 
A recent double-blind, randomized, placebo-controlled trial 
verified that less frequent PTH administration increased lum-
bar spine BMD, radial trabecular bone, and bone formation 
markers in 50 postmenopausal women aged 45 to 70 years 
with a femoral neck BMD T-score between -1.0 and -2.0. 
The administration pattern comprised in one month of daily 
treatment with PTH (1-84) 100 µg, followed by weekly injec-
tions, same dose, for 11 months.47
A recent study using the choice-format conjoint (a survey-
based stated-preference method that focuses on different 
features of the treatment from a patient’s perspective) was 
conducted to measure postmenopausal osteoporosis patients’ 
preferences. The preliminary data analysis of the responses 
from 102 German patients focusing on PTH-specific aspects 
indicates that postmenopausal osteoporotic patients’ prefer-
ences are influenced mostly by features of PTH treatment 
such as ‘storage requirements’, ‘reusability of the pen,’ and 
‘dexterity/easiness for patients to use the pen’.48
These results confirm that an easy-to-use injection pen 
is important to improve patient adherence. The injection pen 
of commercially available PTH (1-84) uses a simple mecha-
nism for daily administration, and refrigeration is not strictly 
necessary, but it must be refilled once a month.17
Large differences still exist in the number of patients 
receiving PTH across different countries, due to differing 
accessibility to PTH as a result of a combination of restrictive 
schedules of reimbursement, high cost, and physicians’ lack 
of knowledge of the potential benefits of PTH.49
Conclusions
Full length PTH, available for the treatment of severe post-
menopausal osteoporosis in Europe, is generally a well toler-
ated and effective treatment for postmenopausal osteoporosis. 
The number of clinical studies is still limited because it is 
not approved as a therapeutic agent in the US.16
The efficacy of PTH (1-84) in the prevention of 
vertebral fractures is well demonstrated, and similar to that 
of teriparatide.34 An effective role in prevention of femoral 
fractures has not yet been documented, but a decrease in 
nonvertebral fractures was seen in high-risk patients,40 
and some data suggest that PTH (1-84) improves femoral 
strength.45 DXA scans have clearly demonstrated the effect on 
bone mass at the spine, and to a lesser extent at the hip.18,20,21 
The increase in volumetric density and bone volume in 
trabecular sites is evident, but a bone volume increase has also 
been detected in cortical sites, which may explain hip fracture 
reduction with PTH treatment.39,16 BMD constantly increases 
with the continuation of the treatment until 36 months,18,20,22,23 
but, after therapy discontinuation, the BMD decreases if an 
antiresorptive treatment is not started.21,23
Hypercalcemia and hypercalciuria are frequent conse-
quences of PTH treatment, but rarely have clinical effects. 
They are usually well controlled by reducing calcium and 
vitamin D supplementation. Calcium levels require only 
periodic measurements.36 Other adverse events, such as 
nausea and vomiting, dizziness, headache, limb pain, and 
hyperuricemia, do not frequently interfere with the continu-
ation of the treatment.International Journal of Women’s Health 2009:1 202
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